FARMINGDALE, N.Y., July 09, 2018 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON ) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today the results of a new Randomized Controlled Trial (RCT), which demonstrated superior healing outcomes associated with the use of ultrasonic debridement for lower extremity wounds.
The study, “ The effect of 22.5kHz low frequency contact ultrasound debridement (LFCUD) on lower extremity wound healing for a vascular surgery population: A Randomized Controlled Trial ” - was published in the International Wound Journal , and compared Misonix’s SonicOne ® ultrasonic debridement device to standard sharp debridement in a 70 patient study conducted by The Ottawa Hospital: Limb Preservation Program in Ottawa, Canada. It concluded that SonicOne ultrasonic debridement treatment resulted in better wound appearance, significant reduction in wound area and superior healing outcomes, compared to other patients in the study that were not treated with SonicOne.
Stavros Vizirgianakis, President and CEO of Misonix , commented, “We are very proud to partner with world class wound care facilities like The Ottawa Hospital: Limb Preservation Program. These results from their recently published study are important both because of the study’s rigor and its conclusive data, which shows marked improvement in healing rates and effectiveness of our SonicOne ultrasonic technology to positively and significantly impact patients’ lives. Wound treatment is an attractive growth opportunity for Misonix and we are confident that our best-in-class ultrasound wound treatment products will allow us to significantly grow across both existing and new markets and drive added adoption of our therapeutic ultrasonic medical devices, including SonicOne.”
Dr. Christine Murphy, lead author of the study, said, “This detailed work is strong evidence that SonicOne improves tissue quality in a challenging population facing very high risk of amputation, including more wound closures. A Randomized Controlled Trial is level one evidence and not commonly available for wound technologies, and as an assessor-blinded study, this is very powerful.”
About Misonix, Inc. Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's web site at www.misonix.com .
| Contact: | |
| Joe Dwyer | Joseph Jaffoni, Norberto Aja, Jennifer Neuman |
| Chief Financial Officer | JCIR |
| Misonix, Inc. | 212-835-8500 or mson@jcir.com |
| 631-694-9555 | |
